{
  "source": "PA-Notification-Zeposia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1375-4\nProgram Prior Authorization/Notification\nMedication Zeposia® (ozanimod)\nP&T Approval Date 12/2021, 12/2022, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nZeposia® (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the\ntreatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,\nrelapsing-remitting disease, and active secondary progressive disease, in adults and moderately\nto severely active ulcerative colitis (UC) in adults.\n2. Coverage Criteriaa:\nA. Multiple Sclerosis\n1. Authorization\na. Zeposia will be approved based on the following criterion:\n(1) Diagnosis of multiple sclerosis (MS)\nAuthorization will be issued for 12 months.\nB. Ulcerative Colitis\n1. Initial Authorization\na. Zeposia will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving Zeposia in combination with a targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz),\nOlumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),\nSimponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab),\nTremfya (guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zeposia will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Zeposia therapy\n-AND-\n(2) Patient is not receiving Zeposia in combination with a targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Olumiant\n(baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab),\nSkyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab), Xeljanz\n(tofacitinib)]\nAuthorization will be i",
    "iant\n(baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab),\nSkyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Zeposia [package insert]. Summit, NJ: Celegene Corporation; August 2024.\nProgram Prior Authorization/Notification – Zeposia (ozanimod)\nChange Control\n12/2021 New program.\n12/2022 Annual review. Added Rinvoq as JAK inhibitor example. Added state\nmandate footnote.\n12/2023 Annual review. Updated not to be used in combination drugs. Updated\nreference.\n12/2024 Annual review. No change to coverage criteria. Updated examples of\nnot to be used in combination with no change to clinical intent.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}